Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1

Next Previous
X
Search
Trial Profile

A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danoprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Ascletis

    • Most Recent Events

    • 30 Jul 2018 According to an Ascletis media release, this phase III study of Ganovo (Danoprevir) won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association and was accepted by Professor Wei Lai, the Director of the Institute of Hepatology of Peking University, also the principal investigator of Ganovos clinical trial.
    • 12 Jun 2018 According to the Ascletis media release, China Food and Drug Administration (CFDA) has approved new drug application for Ganovo for the treatment of viral hepatitis C.
    • 29 Jun 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top